阿拉丁小分子抑制劑、激動劑、拮抗劑--血管生成信號通路(上)

來源: 上海阿拉丁生化科技股份有限公司   2021-1-29   訪問量:549評論(0)

nib Malate≥99%341031-54-7100mg,500mg,1g無細胞VEGFR2 (Flk-1)80 nMPDGFRβ2 nML125046Lenalidomide≥99%191732-72-650mg,250mg,1g,5gPBMCsTNF-α13 nMC126195Cabozantinib (XL184, BMS-907351)≥98%849217-68-15mg,10mg,50mg,100mg,250mg無細胞VEGFR20.035 nMc-Met1.3 nM Ret4 nMKit4.6 nMFlt-1/3/412 nM/11.3 nM/6 nMTie214.3 nMAXL7 nMP127550Ponatinib (AP24534)≥99%943319-70-810mg,50mg,250mg無細胞Abl0.37 nMPDGFRα1.1 nMVEGFR21.5 nMFGFR12.2 nMSrc5.4 nMK125585Ki20227≥98%623142-96-110mg,50mgKDR2 nMVEGFR-212 nMc-Kit451 nMPDGFRβ217 nMA129732Axitinib≥99%319460-85-010mg,50mg,250mg,1g豬主動脈內皮細胞VEGFR10.1 nMVEGFR20.2 nMVEGFR30.1-0.3 nMPDGFRβ1.6 nMc-Kit1.7 nMF127011Foretinib (GSK1363089)≥98%849217-64-75mg,25mg,100mg無細胞Met0.4 nMKDR0.9 nMN129725Nintedanib (BIBF 1120)≥98%656247-17-55mg,10mg,25mg,50mg,100mg,500mg無細胞VEGFR134 nMVEGFR213 nMVEGFR313 nMFGFR169 nMFGFR237 nMFGFR3108 nMPDGFRα59 nMPDGFRβ65 nMV125180Vandetanib (ZD6474)≥99%443913-73-325mg,100mg,500mg無細胞VEGFR240 nMVEGFR3110 nMEGFR500 nMR127804Regorafenib (BAY 73-4506)≥99%755037-03-75mg,10mg,25mg,100mg無細胞VEGFR113 nMVEGFR24.2 nMVEGFR346 nMPDGFR-β22 nMKit7 nMRET1.5 nMRaf-12.5 nMP129722Pazopanib HCl (GW786034 HCl)≥98%635702-64-625mg,100mg,250mg,1g無細胞VEGFR110 nMVEGFR230 nMVEGFR347 nMPDGFR84 nMFGFR74 nMc-Kit140 nMc-fms146 nMC125911Cediranib≥98%288383-20-010mg,50mgVEGFR(KDR)<1 nMFlt1/45 nM/≤3 nMP125865PD173074≥99%219580-11-75mg,10mg,50mgFGFR125 nMVEGFR2100-200 nMD126778Dovitinib (TKI-258, CHIR-258)≥99%405169-16-610mg,50mg,250mg無細胞FLT31 nMc-Kit2 nML126993Linifanib (ABT-869)≥99%796967-16-35mg,10mg,50mgKDR4 nMCSF-1R3 nMFlt-1/33 nM/4 nMPDGFRβ66 nMV125857Vatalanib (PTK787) 2HCl≥99%212141-51-010mg,50mg無細胞VEGFR2/KDR37 nMR127906RAF265 (CHIR-265)≥98%927880-90-81mg,5mg,10mg,50mgVEGFR230 nMB-Raf3-60 nMT126012Tivozanib (AV-951)≥98%475108-18-05mg,25mg,100mgVEGFR10.21 nMVEGFR20.16 nMVEGFR30.24 nMM129736Motesanib Diphosphate (AMG-706)≥98%857876-30-35mg,10mg,50mgVEGFR12 nMVEGFR23 nMVEGFR36 nML125518Lenvatinib (E7080)≥99%417716-92-85mg,10mg,50mg,100mgVEGFR2(KDR)4 nMVEGFR3(Flt-4)5.2 nMB127317Brivanib (BMS-540215)≥98%649735-46-65mg,10mg,50mg VEGFR225 nMM127064MGCD-265≥98%875337-44-31mg,5mg,10mg,50mgc-Met1 nMVEGFR1/2/33 nM/3 nM/4 nMA126830AEE788 (NVP-AEE788)≥97%497839-62-05mg,25mg,100mgEGFR2 nMHER2/ErbB26 nME126318ENMD-2076≥99%934353-76-15mg,10mg,50mgAurora A14 nMFlt31.86 nMO126155OSI-930≥99%728033-96-31mg,5mg,25mg,50mgKit80 nMKDR9 nMCSF-1R15 nMC126929CYC116≥99%693228-63-61mg,10mg,50mgAurora A8.0 nMAurora B9.2 nMVEGFR244 nMK125876Ki8751≥98%228559-41-95mg,25mg,100mg VEGFR20.9 nMT129747Telatinib≥99%332012-40-51mg,5mg,10mg,50mgVEGFR2/36 nM/4 nMc-Kit1 nMPDGFRα15 nMP126419PP121≥98%1092788-83-410mg,50mgPDGFR2 nMHck8 nMmTOR10 nMVEGFR212 nMSrc14 nMAbl18 nMDNA-PK60 nMP125184Pazopanib≥99%444731-52-625mg,100mg,500mgGFR110 nMVEGFR230 nMVEGFR347 nMPDGFR84 nMFGFR74 nMc-Kit140 nMc-Fms/CSF1R146 nMK125907KRN-633≥97%286370-15-85mg,25mg,100mgVEGFR1170 nMVEGFR2160 nMVEGFR3125 nMS126571SAR131675≥99%1433953-83-31mg,10mg,50mg VEGFR323 nM12 nMB129768BMS-794833≥99%1174046-72-01mg,5mg,10mg,50mgMet1.7 nMVEGFR215 nMS125098Sorafenib≥99%284461-73-0250mg,1g無細胞Raf-16 nMB-Raf22 nMVEGFR-290 nMVEGFR-320 nMPDGFR-β57 nMFlt-359 nMc-KIT68 nMC129757Cabozantinib malate (XL184)≥99%1140909-48-310mg,25mg,50mg,100mg,250mgVEGFR20.035 nMc-Met1.3 nMRet4 nMKit4.6 nMFlt-1/3/412 nM/11.3 nM/6 nMTie214.3 nMAXL7 nMB129764Brivanib Alaninate (BMS-582664)≥95%649735-63-710mg,50mgVEGFR225 nME126304Golvatinib (E7050)≥99%928037-13-21mg,5mg,10mg,50mgc-Met14 nMVEGFR-216 nMZ129748ZM 306416≥98%690206-97-410mg,50mgVEGFR10.33 μMEGFR<10 nMZ129761ZM 323881 HCl≥99%193000-39-41mg,10mg,50mg VEGFR2<2 nME129946ENMD-2076 L-(+)-Tartaric acid≥99%1291074-87-75mg,25mgAurora A14 nMVEGFR(Flt3)1.86 nML126507LY2874455≥99%1254473-64-75mg,10mg,50mgFGFR12.8 nMFGFR22.6 nMFGFR36.4 nMFGFR46 nMVEGFR27 nMS167823SU149898% (HPLC)168835-82-35mg,25mgKDR0.7 μMD126474DCC-2618-1225278-16-95mg,10mg,50mg S126061蘇尼替尼0.99557795-19-4100mg,500mg,1g,5g,25gVEGFR2(Flk-1)80 nMPDGFRβ2 nMD1673182-D0898% (HPLC)144707-18-65mg,25mgAxl0.49 nMIRAK43.9 nMROS15.3 nMMLK49.8 nMGSK3β11 nMRET11 nMKDR17 nMPI3Kα35 nM

*BTK

產品號產品名稱規格CAS包裝靶點IC50
P127143Ibrutinib (PCI-32765)≥98%936563-96-15mg,10mg,50mg,250mgBTK0.5 nM
A127694AVL-29298%1202757-89-85mg,10mg,50mg,100mgBTK0.5 nM
O173511Olmutinib97%1353550-13-65mg,100mg  

*PDGFR

KDR0.86 nM

產品號產品名稱規格CAS包裝細胞靶點IC50
S129593Sorafenib Tosylate≥99%475207-59-150mg,100mg,250mg,1g,5g無細胞Raf-16 nM
VEGFR2/Flk115 nM
無細胞B-Raf22 nM
B-Raf (V599E)38 nM
PDGFRβ57 nM
mPDGFRβ57 nM
FLT358 nM
c-Kit68 nM
VEGFR290 nM
FGFR1580 nM
I129225Imatinib Mesylate (STI571)≥99%220127-57-1100mg,250mg,1g,5g,25g無細胞PDGFR100 nM
c-Kit100 nM
v-Abl600 nM
E129728Sunitinib Malate≥99%341031-54-7100mg,500mg,1g無細胞PDGFRβ 2 nM
VEGFR280 nM
FLT3
Kit
P127550Ponatinib (AP24534)≥99%943319-70-810mg,250mg,50mg無細胞Abl0.37 nM
PDGFRα1.1 nM
VEGFR21.5 nM
FGFR12.2 nM
c-Src5.4 nM
c-Kit12.5 nM
A129732Axitinib≥99%319460-85-010mg,250mg,50mg,1gVEGFR1/FLT10.1 nM
VEGFR2/Flk10.18 nM
VEGFR2/KDR0.2 nM
VEGFR30.1 nM-0.3 nM
PDGFRβ1.6 nM
Kit1.7 nM
PDGFRα5.0 nM
I124963Imatinib (STI571)≥99%152459-95-51g,5g,25g,250mgPDGFR100 nM
c-Kit100 nM
v-Abl600 nM
F127011Foretinib (GSK1363089)≥99%849217-64-75mg,100mg,25mg無細胞Met0.4 nM
 Tie-21.1 nM
VEGFR3/FLT42.8 nM
RON3 nM
FLT33.6 nM
PDGFRα3.6 nM
Kit6.7 nM
VEGFR1/FLT16.8 nM
PDGFRβ9.6 nM

*Src

項目號產品名稱規格CAS包裝細胞靶點IC50
D125110Dasatinib≥99%302962-49-825mg,100mg,500mg,1g,5g無細胞Abl 0.6 nM
Src0.8 nM
c-Kit (D816V)37 nM
c-Kit (wt)79 nM
P127550Ponatinib (AP24534)≥99%943319-70-810mg,50mg,250mg無細胞Abl0.37 nM
PDGFRα1.1 nM
VEGFR21.5 nM
FGFR12.2 nM
c-Src5.4 nM
c-Kit12.5 nM
B129905Bosutinib (SKI-606)≥99%380843-75-410mg,50mg,100mgS6 kinase
ERK
STAT3
無細胞Abl1 nM
Src1.2 nM
P125444Pelitinib≥98%257933-82-75mg,25mg,100mgEGFR38.5 nM
Src282 nM
MEK/ERK800 nM
ErbB2 1.255 μM
Raf 3.353 μM
K126255KX2-391≥99%897016-82-91mg,5mg,10mg,50mgSrc (HuH7)9 nM
Src (PLC/PRF/5)13 nM
Src (Hep 3B)26 nM
Src (Hep G2)60 nM
N127928NVP-BHG712≥98%940310-85-05mg,25mg,100mgEphB425 nM(ED50)
C-Raf0.395 μM
c-Src1.266 μM
c-Abl1.667 μM
E126318ENMD-2076≥99%934353-76-15mg,10mg,50mgFLT31.86 nM
RET10.4 nM
Aurora A14 nM
VEGFR3/FLT415.9 nM
Src20.2 nM
NTRK1/TRKA24.2 nM
CSF-1R/c-Fms24.8 nM
LCK43.7 nM
FAK54.9 nM
PDGFRα56.4 nM
VEGFR2/KDR58.2 nM
BLK69.4 nM
FGFR270.8 nM
YES178.4 nM
Abl1 (T315I)81.3 nM
FGFR192.7 nM
Fyn112 nM
JAK2120 nM
Kit120 nM
Aurora B350 nM
P129908PRT062607 (P505-15, BIIB057) HCl≥98%1370261-97-45mg,25mg,無細胞Syk1 nM
FGR81 nM
MLK188 nM
PYK2108 nM
YES123 nM
FLT3139 nM
PAK5166 nM
Lyn192 nM
cSRC244 nM
LCK249 nM
FAK415 nM
P125361PP2≥98%172889-27-95mg,25mg,100mg無細胞LCK4 nM
Fyn5 nM
P126419PP121≥98%1092788-83-410mg,50mgPDGFR2 nM
Hck8 nM
VEGFR12 nM
mTOR13 nM
Src14 nM
Abl18 nM
p110α52 nM
DNA-PK60 nM
p110δ150 nM
EphB4190 nM
Q111274槲皮素95.00%117-39-51g,10g,50g,250gSirtuin 
Src 
PKC 
PI3Kγ2.4 μM
PI3Kδ3.0 μM
PI3Kβ5.4 μM
Q111273槲皮素分析標準品,≥98.5%117-39-520mgSirtuin 
Src 
PKC 
PI3Kγ2.4 μM
PI3Kδ3.0 μM
PI3Kβ5.4 μM

*Syk

項目號產品名稱規格CAS包裝細胞靶點IC50
R129913R788 (Fostamatinib) Disodium≥98%1025687-58-450mg,1mg,5mg,10mg無細胞Syk41 nM
R129910R406 (free base)≥99%841290-80-025mg,50mg,100mg,5mg,10mg無細胞Syk41 nM
FLT3
P129908PRT062607 (P505-15, BIIB057) HCl≥98%1370261-97-45mg,25mg無細胞Syk1 nM
FGR81 nM
MLK188 nM
PYK2108 nM
YES123 nM
FLT3139 nM
PAK5166 nM
Lyn192 nM
cSRC244 nM
LCK249 nM
FAK415 nM
F129915Fostamatinib (R788)≥98%901119-35-5 50mg,5mg,10mgSyk41 nM
Adenosine A3 receptor 81 nM
Adenosine transporter1.84 μM
Monoamine transporter2.74 μM

*VDA

項目號產品名稱規格CAS包裝細胞靶點IC50Ki
D129922DMXAA (Vadimezan)≥98% 117570-53-3 5mg,25mg,100mg,250mg無細胞DT-diaphorase62.5 μM20 μM
P126141Plinabulin (NPI-2358)≥97%714272-27-25mg,10mg,50mg,1g腫瘤細胞
Tubulin
9.8~18 nM
V129759 Verteporfin≥97%129497-78-525mg,50mg,1mg,5mg,10mg
VDA
YAP/TEAD interaction  
,
阿拉丁小分子抑制劑、激動劑、拮抗劑--血管生成信號通路(上)

血管生成

血管生成,即從已存在的血管中生成新血管。此通路是通過人體中存在的諸多互補和復雜的信號途徑調節的。正常情況下,血管生成的相關誘導劑和抑制劑之間保持平衡狀態。但對于創傷、缺氧或炎癥繼發等微環境破壞的條件下,此通路能做出迅速的應答。在各種慢性病理和腫瘤的情況下,血管生成的平衡狀態被打破,導致異常的血管生成或新生血管。

血管生成信號通路轉導過程

血管生成的激活導致促血管生成生長因子(VEGF、PDGF、FGF和TGF等)的釋放,這些因子將其受體結合到已有血管內的內皮細胞上,從而誘導PI3K/Akt、Erk1/2、Smad和Notch等多種途徑的信號轉導,引起內皮細胞增殖和遷移。內皮細胞利用基質金屬蛋白酶和整合素來消化細胞外基質,遷移到新的區域,在那里它們延長并形成管子,產生新的血管。
在腫瘤血管生成過程中,癌細胞刺激新血管的形成,為腫瘤輸送氧氣和營養。隨著腫瘤的生長,位于腫瘤中心的細胞缺氧,使得轉錄因子HIF-1α(缺氧誘導因子-1)穩定表達。該轉錄因子與HIF-1β結合上調幾種促血管生成基因的表達。此外,生長因子信號還刺激HIF-1活性,以維持生長細胞的氧穩態。

血管生成信號通路圖

產品列表

*FLT

項目號產品名稱規格CAS包裝細胞靶點IC50Ki
S129593Sorafenib Tosylate≥99%475207-59-150mg,100mg,250mg,1g,5g無細胞Raf-16 nM
B-Raf22 nM
VEGFR-290 nM
VEGFR-320 nM
PDGFR-β57 nM
Flt-359 nM
c-KIT68 nM
T127762Tozasertib≥98%639089-54-625mg,100mgFLT330 nM
S125267SP600125≥98%129-56-625mg,100mg,500mg,1g,5g無細胞JNK140 nM
JNK240 nM
JNK390 nM
F127011Foretinib (GSK1363089)≥98%849217-64-75mg,25mg,100mg無細胞Met0.4 nM
KDR0.9 nM
Q127558Quizartinib (AC220)≥99%950769-58-15mg,10mg,50mg,500mgMV4-11Flt3(ITD)1.1 nM/4.2 nM
RS4;11Flt3(WT)1.1 nM/4.2 nM
D126778Dovitinib (TKI-258, CHIR-258)≥99%405169-16-610mg,50mg,250mg無細胞FLT31 nM
c-Kit2 nM
T126330Fedratinib (SAR302503, TG101348)≥98%936091-26-85mg,25mg,100mg無細胞JAK23 nM
L126993Linifanib (ABT-869)≥99%796967-16-35mg,10mg,50mgKDR4 nM
CSF-1R3 nM
Flt-1/33 nM/4 nM
PDGFRβ66 nM
C127776Crenolanib (CP-868596)≥99%670220-88-95mg,10mg,50mgPDGFRα2.1 nM
PDGFRβ3.2 nM
R129910R406 (free base)≥99%841290-80-05mg,10mg,25mg,50mg,100mg Syk41 nM
M127412Amuvatinib (MP-470)≥98%850879-09-35mg,25mg,100mgc-Kit10 nM
PDGFα40 nM
Flt381 nM
T125150Tandutinib (MLN518)≥98%387867-13-225mg,100mg,500mg FLT30.22 μM
T127523TG10120998%936091-14-45mg,25mg,100mg無細胞JAK26 nM
Flt325 nM
RET17 nM
K127169KW-2449≥98%1000669-72-65mg,25mg,100mg Flt36.6 nM
E126318ENMD-2076≥99%934353-76-15mg,10mg,50mgAurora A14 nM
Flt31.86 nM
L127618LDK378≥99%1032900-25-65mg,25mg,100mg,250mg無細胞ALK0.2 nM
IGF-1R8 nM
InsR7 nM
STK22D23 nM
FLT360 nM
P129908PRT062607 (P505-15, BIIB057) HCl≥98%1370261-97-45mg,25mg無細胞Syk1 nM
S125098Sorafenib≥99%284461-73-0250mg,1g無細胞Raf-16 nM
B-Raf22 nM
VEGFR-290 nM
VEGFR-320 nM
PDGFR-β57 nM
Flt-359 nM
c-KIT68 nM
C129757Cabozantinib malate (XL184)≥99%1140909-48-310mg,25mg,50mg,100mg,250mgVEGFR20.035 nM
無細胞c-Met1.3 nM
Ret4 nM
Kit4.6 nM
Flt-1/3/412 nM/11.3 nM/6 nM
Tie214.3 nM
AXL7 nM
T129806TCS 359≥99%301305-73-710mg,25mg,50mg FLT343 nM
E129946ENMD-2076 L-(+)-Tartaric acid≥99%1291074-87-75mg,25mgAurora A14 nM
VEGFR(Flt3)1.86 nM
L127298LY2801653-1206799-15-65mg,10mg,50mg MET2 nM
C168062Crotonoside95% (HPLC)1818-71-95mg,10mg,25mgFLT3
HDAC3/6
G172979Gilteritinib97%1254053-43-45mg,100mgFLT30.29 nM
AXL0.73 nM
P171724Pexidartinib97%1029044-16-35mg,100mgCSF-1R20 nM
Kit10 nM
FLT3160 nM 

*DNA alkylator

項目號產品名稱規格CAS包裝細胞靶點IC50EC50Ki
S129593Sorafenib Tosylate≥99%475207-59-110mg,50mg,250mg,1g,5g無細胞Raf-16 nM
B-Raf22 nM
VEGFR-290 nM
VEGFR-320 nM
PDGFR-β57 nM
Flt-359 nM
c-KIT68 nM
E129728Suniti



上海阿拉丁生化科技股份有限公司   商家主頁

地址:上海市浦東新區新金橋路196號6樓
聯系人:丁博士
電話:400-620-6333
傳真:021-50323701
Email:sale@aladdin-e.com

韩国免费无遮挡在线观看_日本牲交大片免费观看_毛片曰本女人牲交视频视频